119 related articles for article (PubMed ID: 31181959)
1. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
2. SGLT2 inhibitors: not every drug has the same effect.
Staruschenko A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
[No Abstract] [Full Text] [Related]
3. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
Layton AT; Vallon V
Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
Kume S; Packer M
Kidney Int; 2024 Jun; 105(6):1172-1176. PubMed ID: 38777403
[No Abstract] [Full Text] [Related]
5. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitor: 2-way superstar in nephrology?
Nangaku M
Kidney Int; 2024 Jun; 105(6):1176-1177. PubMed ID: 38777404
[No Abstract] [Full Text] [Related]
7. SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?
de Boer IH; Kahn SE
J Am Soc Nephrol; 2017 Jan; 28(1):7-10. PubMed ID: 27539605
[No Abstract] [Full Text] [Related]
8. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
Yau K; Cherney DZI; van Raalte DH; Wever BE
Kidney Int; 2024 Jun; 105(6):1168-1172. PubMed ID: 38777402
[No Abstract] [Full Text] [Related]
9. [Cardiac and renal protective effects of SGLT2 inhibitors].
La L; Maione L
Rev Med Interne; 2024 Jun; 45(6):323-326. PubMed ID: 38857975
[No Abstract] [Full Text] [Related]
10. Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia.
Seetharaman R; Joshi SS
J Clin Lipidol; 2023; 17(3):420-421. PubMed ID: 37137801
[No Abstract] [Full Text] [Related]
11. Targeting senescence with SGLT2 inhibitors.
Le Bras A
Lab Anim (NY); 2024 Jul; 53(7):176. PubMed ID: 38914825
[No Abstract] [Full Text] [Related]
12. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors.
Gunasekaran D; Shirali AC
Kidney360; 2023 Sep; 4(9):e1322-e1324. PubMed ID: 37487034
[No Abstract] [Full Text] [Related]
13. SGLT2 Inhibition and Tubular Sodium Handling.
Palmer BF; Clegg DJ
J Am Soc Nephrol; 2024 Feb; 35(2):131-133. PubMed ID: 38129943
[No Abstract] [Full Text] [Related]
14. CREDENCE: A silver lining in the dark cloud of diabetic nephropathy.
Hanai K; Babazono T
J Diabetes Investig; 2020 May; 11(3):527-529. PubMed ID: 31705732
[No Abstract] [Full Text] [Related]
15. SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
Packer M
J Am Coll Cardiol; 2024 Apr; 83(15):1399-1402. PubMed ID: 38599716
[No Abstract] [Full Text] [Related]
16. Sodium glucose cotransporter 2 inhibitor as a promising therapy for congestive kidney injury.
Haruhara K; Kubo E
Hypertens Res; 2024 Feb; 47(2):568-570. PubMed ID: 38001167
[No Abstract] [Full Text] [Related]
17. Inhibiting SGLT2 to manage hypertension in rats.
Ferreira J
Lab Anim (NY); 2023 Dec; 52(12):286. PubMed ID: 38017165
[No Abstract] [Full Text] [Related]
18. Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
[TBL] [Abstract][Full Text] [Related]
19. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Hess DA; Terenzi DC; Trac JZ; Quan A; Mason T; Al-Omran M; Bhatt DL; Dhingra N; Rotstein OD; Leiter LA; Zinman B; Sabongui S; Yan AT; Teoh H; Mazer CD; Connelly KA; Verma S
Cell Metab; 2019 Oct; 30(4):609-613. PubMed ID: 31477497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
